(Q73483002)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

main subject

doxorubicin

0 references

hepatocellular carcinoma

1 reference

U Halm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

G Etzrodt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

I Schiefke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

F Schmidt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

H Witzigmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J Mössner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

F Berr

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

113-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

4 November 2019

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1023%2FA%3A1008386822906

inferred from DOI database lookup

7 January 2021

based on heuristic

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

Crossref

https://api.crossref.org/works/10.1023%2FA%3A1008386822906

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes

1 reference

Crossref

https://api.crossref.org/works/10.1023%2FA%3A1008386822906

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1023/A:1008386822906

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10690399%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference